Cover Image
市場調查報告書

Noxxon Pharma AG : 產品平台分析

Noxxon Pharma AG - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224721
出版日期 內容資訊 英文 36 Pages
訂單完成後即時交付
價格
Back to Top
Noxxon Pharma AG : 產品平台分析 Noxxon Pharma AG - Product Pipeline Review - 2016
出版日期: 2016年09月30日 內容資訊: 英文 36 Pages
簡介

Noxxon Pharma AG 是臨床階段的生物科技企業,正在開發醫療產業用新的獨家治療方法。該公司特別致力於發炎性疾病和血液疾病,糖尿病,腎臟疾病,腫瘤學,發炎及止痛方法的開發。

本報告提供Noxxon Pharma AG的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃相關等資訊。

Noxxon Pharma AG的基本資料

  • Noxxon Pharma AG概要
  • 主要資訊
  • 企業資料

Noxxon Pharma AG:R&D概要

  • 主要的治療範圍

Noxxon Pharma AG:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Noxxon Pharma AG:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第Ⅱ階段的產品/聯合治療模式
    • 第Ⅰ階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Noxxon Pharma AG:藥物簡介

  • emapticap pegol
  • lexaptepid pegol
  • olaptesed pegol
  • NOXD-19
  • NOXD-20
  • NOXG-15
  • NOXG-16
  • NOXL-41
  • NOXS-93

Noxxon Pharma AG:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Noxxon Pharma AG:最近的開發平台趨勢

Noxxon Pharma AG:暫停中的計劃

Noxxon Pharma AG:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08147CDB

Summary

Global Markets Direct's, 'Noxxon Pharma AG - Product Pipeline Review - 2016', provides an overview of the Noxxon Pharma AG's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Noxxon Pharma AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Noxxon Pharma AG
  • The report provides overview of Noxxon Pharma AG including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Noxxon Pharma AG's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Noxxon Pharma AG's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Noxxon Pharma AG's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Noxxon Pharma AG
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Noxxon Pharma AG's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Noxxon Pharma AG Snapshot
    • Noxxon Pharma AG Overview
    • Key Facts
  • Noxxon Pharma AG - Research and Development Overview
    • Key Therapeutic Areas
  • Noxxon Pharma AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Noxxon Pharma AG - Pipeline Products Glance
    • Noxxon Pharma AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Noxxon Pharma AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Noxxon Pharma AG - Drug Profiles
    • emapticap pegol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lexaptepid pegol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOXD-19 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOXD-20 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOXD-21 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOXG-15 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOXG-16 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOXL-41 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOXS-93 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • olaptesed pegol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Noxxon Pharma AG - Pipeline Analysis
    • Noxxon Pharma AG - Pipeline Products by Target
    • Noxxon Pharma AG - Pipeline Products by Route of Administration
    • Noxxon Pharma AG - Pipeline Products by Molecule Type
    • Noxxon Pharma AG - Pipeline Products by Mechanism of Action
  • Noxxon Pharma AG - Dormant Projects
  • Noxxon Pharma AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Noxxon Pharma AG, Key Facts
  • Noxxon Pharma AG - Pipeline by Indication, 2016
  • Noxxon Pharma AG - Pipeline by Stage of Development, 2016
  • Noxxon Pharma AG - Monotherapy Products in Pipeline, 2016
  • Noxxon Pharma AG - Phase II, 2016
  • Noxxon Pharma AG - Phase I, 2016
  • Noxxon Pharma AG - Preclinical, 2016
  • Noxxon Pharma AG - Pipeline by Target, 2016
  • Noxxon Pharma AG - Pipeline by Route of Administration, 2016
  • Noxxon Pharma AG - Pipeline by Molecule Type, 2016
  • Noxxon Pharma AG - Pipeline Products by Mechanism of Action, 2016
  • Noxxon Pharma AG - Dormant Developmental Projects,2016
  • Noxxon Pharma AG, Subsidiaries

List of Figures

  • Noxxon Pharma AG - Pipeline by Top 10 Indication, 2016
  • Noxxon Pharma AG - Pipeline by Stage of Development, 2016
  • Noxxon Pharma AG - Monotherapy Products in Pipeline, 2016
  • Noxxon Pharma AG - Pipeline by Target, 2016
  • Noxxon Pharma AG - Pipeline by Route of Administration, 2016
  • Noxxon Pharma AG - Pipeline by Molecule Type, 2016
  • Noxxon Pharma AG - Pipeline Products by Mechanism of Action, 2016
Back to Top